Novartis

By Brian Dolan 02:02 pm January 19, 2011
We mentioned a report last week from the Digital Pharma Blog that Pfizer, Johnson & Johnson and Merck had each removed apps from the Apple AppStore in recent months. While many others covering this story attributed the move to a potential rethinking on the value of apps, the Digital Pharma Blog attributes many of the withdrawals to mergers the companies went through during the past two years...
By Brian Dolan 07:01 am November 10, 2010
Within the next 18 months, Novartis plans to seek regulatory approval for Proteus Biomedical's microchipped pills, which tracks medication adherence by time-stamping the patients ingestion of medications. Novartis global head of development Trevor Mundel told attendees at the recent Reuters Health Summit in New York that it will submit the smart pill system for regulatory approval in Europe...
By Brian Dolan 07:16 am August 24, 2010
That is, at least, according to a new study published in Obstetrics & Gynecology: Daily text message reminders did not help the 82 women in the study become more adherent to their birth control pill regimen. Both the text-receiving participants and the control group missed about 5 pills per month. (Worth noting perhaps that, according to a report in the Wall Street Journal about the study,...
By Brian Dolan 01:28 pm August 12, 2010
The United Kingdom's National Health Service plans to begin piloting Proteus Biomedical's "smart pills" this month to help curb health costs due to medication non-adherence among heart failure patients, according to a report in the Financial Times. The Royal Berkshire and Imperial College healthcare trusts are currently looking for 40 patients for the clinical trial, which will last four months....
By Brian Dolan 05:47 am April 26, 2010
Text4Baby update: Forty states are in the process of creating Text4Baby coalitions and encouraging nurses to talk up the program, according to a recent report in Time magazine. The report also notes that another major television channel, besides MTV, is also promoting the text message powered service: Telemundo. More iPlato has a new customer, this time outside of the UK: Lexum European Eye...
By Brian Dolan 08:45 am April 21, 2010
The FDA announced today that it has cleared Proteus Biomedical's wireless, adhesive sensor technology Raisin, which can track and record a patient's heart rate, physical activity, body position and other biometrics. Raisin then transmits the data via Bluetooth to a PC or mobile device. Proteus explains that the Raisin device is worn just like a bandaid. Raisin, however, is just one part of the...
By Brian Dolan 12:35 am January 21, 2010
It's a widely known statistic that between one-third and one-half of patients in the U.S. do not take their medications as instructed, which leads to poorer health, more frequent hospitalization, a higher risk of death and up to $290 billion each year in increased medical costs. Stacked against that figure, Novartis' recent $24 million investment in intelligent medicine / medication adherence...
By Brian Dolan 03:23 am January 19, 2010
According to a report in the Economist, pharmaceuticals company Novartis' $24 million investment in intelligent medicine startup Proteus Biomedical may be just as important in the long run as Novartis' $50 billion takeover of eye-care firm, Alcon. Proteus Biomedical's venture capital round actually brought in $25.4 million, which makes us wonder if the difference came from an additional...
By Brian Dolan 03:47 am January 12, 2010
Pharmaceutical giant Novartis announced that would invest $24M in upfront cash and equity as part of an exclusive worldwide agreement for the pharma company to license Proteus Biomedical's sensing technology for organ transplantation. (That must be the kind of exclusive deal Novartis had in mind when the two companies announced their collaboration on a pilot last year.) As part of the deal,...
By Brian Dolan 10:42 am January 11, 2010
Bedford, Massachusetts-based MicroCHIPS recently announced another $16.5 million in venture capital. The company is developing an implantable medical device that will deliver drugs inside the body. This third round of funding brings the company's total funding to just north of $70 million, according to the company. InterWest Partners joined previous investors Polaris Venture Partners, Flybridge...